請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/54774
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 潘子明 | |
dc.contributor.author | Chih-Heng Lee | en |
dc.contributor.author | 李志恆 | zh_TW |
dc.date.accessioned | 2021-06-16T03:38:16Z | - |
dc.date.available | 2015-08-11 | |
dc.date.copyright | 2015-08-11 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-03-29 | |
dc.identifier.citation | 行政院衛生福利部。1999。健康食品安全及功效評估方法。
行政院衛生福利部國民健康局。2003。高血脂防治手冊。 行政院衛生福利部。2006。健康食品之輔助調節血壓功能評估方法。 行政院衛生福利部。2007。紅麴健康食品規格標準。 行政院衛生福利部。2009。人體試驗管理辦法。 行政院衛生福利部。2013。101年國人主要死因統計結果。 林讚峰。1983。紅麴菌的鑑定及實用分類法。製酒科技專論彙論。5: 104-113。 林讚峰。1992。紅麴菌研究發展之演進。科學農業。40: 193-198。 林讚峰。1994。紅麴菌的特性及應用。生物產業。5: 29-35。 林讚峰。1995。紅麴菌培養工藝及紅麴應用之演進。製酒科技專論彙論。17: 156-158。 吳政倫。2008。含 γ-胺基丁酸與血管收縮素 I 轉化酶抑制劑紅麴山藥之最適化生產與降血壓功效評估。國立臺灣大學微生物與生化學研究所碩士論文。 區少梅。2002。吃 GABA 降血壓-神奇的 γ-胺基丁酸。元氣齋出版社。台北。台灣。 陳彥霖、李昭蓉、陳建州與袁國芳。1998。紅麴菌種的研究開發與應用。食品工業月刊。30: 1-10。 陳慶源、莊淑惠。2003。綜論紅麴產品之開發應用。食品工業。35: 1-2。 莊宗憲。2012。續發性高血脂症之原因簡介。臺灣醫界雜誌。55 : 19-20。 國民健康局。2007。成人(20歲以上)代謝症候群之判定標準。台灣。http://www.bhp.doh.gov.tw 蔡秋帆、湯念湖、及王耀宏。2002。藥理學。新文京開發出版有限公司。台北。台灣。 蘇遠志與黃冬梨。1981。紅麴色素之動物飼養試驗。國立台灣大學農學院研究報告。21:98-112。 American Heart Association [AHA]. 2014. Cold and flu medications can increase blood pressure. Dallas, TX, U.S. Available from: www.heart.org/HEARTORG/. Accessed Dec 10. Akihisa, T., Tokuda, H., Ukiya, M., Kiyota, A., Yasukawa, K., Sakamoto, N., Kimura, Y., Suzuki, T., Takayasu, J., Nishino, H. 2005. Anti-tumor-initiating effects of monascin, an azaphilonoid pigment from the extract of Monascus pilosus fermented rice (red-mold rice). Chem. Biodiversity. 2: 1305-1309. Alberto, M. S., Jose, F. C., Samir, K. A., Josep, G. 2004. New and interesting species of Monascus from soil, with a key to the known species. Stud. Mycol. 50: 299-306. Alberti, K. G., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J. C., James, W. P., Loria, C. M., Smith, S. C. 2009. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention. National Heart, Lung, and Blood Institute. American Heart Association. World Heart Federation. International Atherosclerosis Society. and International Association for the Study of Obesity. Circulation. 120: 1640-1645. Aniya, Y., Yokomakura, T., Yonamine, M., Shimada, K., Nagamine, T., Shimabukuro, M., Gibo H. 1999. Screening of antioxidant action of various molds and protection of Monascus anka against experimentally induced liver injuries of rats. Gen. Pharmacol. 32: 225-231. August, P. 2003. Initial treatment of hypertension. N. Engl. J. Med. 348: 610-617. Bardage, C., Isacson, D. G. L. 2000. Self-reported side-effects of antihypertensive drugs: an epidemiological study on prevalence and impact on health-state utility. Blood pressure. 9: 328-334. Blanc, P. J., Loret, M. O., Santerre, A. L., Pareilleux, A., Prome, D., Prome, J. C., Laussac, J. P., Goma, G. 1994. Pigments of Monascus. J. Food Sci. 59: 862-865. Blanc, P. J., Laussac, J. P., Le Bars, J., Le Bars, P., Loret, M. O., Pareilleux, A., Prome, D., Prome, J. C., Santerre, A. L., Goma, G. 1995. Characterization of monascidin A from Monascus as citrinin. Int. J. Food. Microbiol. 27:201-213. Brown, M.S., Golstein, J. L. 1984. How LDL receptors influence cholesterol and atherosclerosis. Sci. Amer. 251: 52-60. Carl, J., Vaugha, M. D., Antonio, M., Gotto, M. D., Craig, T., Basson, M. D. 2000. The evolving role of statins in the management of atherosclerosis. J. Am. Coll. Cardiol. 35: 1-10. Carretero, O. A., Oparil, S. 2000. Essential hypertension. Part I: Definition and etiology. Circulation. 101 : 329–335. Chan, C. W. H., Thompson, D. R. 2006. The use of placebo in clinical nursing research. J. Clin. Nurs. 15: 521-524. Chen, W. P., Ho, B. Y., Lee, C. L., Lee, C. H. Pan, T. M. 2008. Red mold rice prevents the development of obesity, dyslipidemia and hyperinsulinemia induced by high-fat diet. Int. J. Obes. 32: 1694-1704. Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, Jr. J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, Jr. J. T., Roccella, E. J. 2003. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure'. Hypertension. 42: 1206-1252. Daniel, S., Sampath, P., Thomas, E. C., John, C. K., Joseph, L. W. 1989. Beyond cholesterol modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320: 915-924. Endo, A. 1969. A new hypocholesterolemic agent produced by a Monascus species. J. Antibiot. 32: 852-854. Endo, A. 1980. Monacolin K, a new hypocholesterolemic agent that specifically inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase. J. Antibiot. 33: 334-336. Evans, M. 2000. Justified deception? The single blind placebo in drug research. Journal of Medical Ethics 26:188-193. Fabre, C. E., Santerre, A. L., Loret, M. O., Baberian, R., Pareilleux, A., Goma, G., Blanc, P. J. 1993. Production and food application of the red pigments of Monascus ruber. J. Food Sci. 58: 1099-1102. Fredrickson, D. S., Lees, R. S. 1965. A system for phenotyping hyperlipoproteinemia . Circulation. 31: 321-327. Friedman, S. F., Martin, P., Munoz, J. S. 2003. Laboratory evaluation of the patient with liver disease. Hepatology, a textbook of liver disease. Philedelphia: Saunders publication. 661-709 p. Giannini, E. G., Testa, R., Savarino, V. 2005. Liver enzyme alteration: a guide for clinicians. Can. Med. Assoc. J. 172: 367-379. Gross, J. L., de Azevedo, M. J., Silveiro, S. P., Canani, L. H., Caramori, M. L., Zelmanovitz, T. 2005. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 28: 164-176. Gropper, S., Smith, J. 2012. Advanced nutrition and human metabolism. 6th ed. Belmont: Wadesworth. 455-479 p. Ho, B. Y., Pan, T. M. 2009. The Monascus metabolite monacolin K reduces tumor progression and metastasis of Lewis lung carcinoma cells. J. Agric. Food Chem. 57: 8258-8265. Hsu, W. H., Lee, B. H., Pan, T. M. 2010a. Red mould dioscorea-induced G2/M arrest and apoptosis in human oral cancer cells. J. Sci. Food Agric. 90: 2709-2715. Hsu, W. H., Lee, B. H. Pan, T. M. 2010b. Protection of Monascus-fermented dioscorea against DMBA-induced oral injury in hamster by anti-inflammatory and antioxidative potentials. J. Agric. Food Chem. 58: 6715-6720. Hsu, W. H., Lee, B. H. Pan, T. M. 2011. Effects of red mold dioscorea on oral carcinogenesis in DMBA-induced hamster animal model. Food Chem. Toxicol. 49: 1292-1297. Kaplan, N. M. 1989. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch. Intern. Med. 149: 1514-1520. Kinosian, B., Glick, H., Garland, G. 1994. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann. Intern. Med. 121: 641-647. Kohama, Y., Matsumoto, S., Mimura, T., Tanabe, N., Inada, A., Nakanishi, T. 1987. Isolation and identification of hypotensive principles in red-mold rice. Chem. Pharm. Bull. 35: 2484-2489. Lee, B. H., Hsu, W. H., Hsu, Y. W., Pan, T. M. 2013. Dimerumic acid protects pancreas damage and elevates insulin production in methylglyoxal-treated pancreatic RINm5F cells. J. Fun. Food. 5: 642-650. Lee, C. L., Tsai, T. Y., Wang, J. J., Pan, T. M. 2006a. In vivo hypolipidemic effects and safety of low dosage Monascus powder in a hamster model of hyperlipidemia. Appl. Microbiol. Biotechnol. 70: 533-540. Lee, C. L., Wang, J. J., Kuo, S. L. Pan, T. M. 2006b. Monascus fermentation of dioscorea for increasing the production of cholesterol-lowering agent-monacolin K and antiinflammation agent-monascin. Appl. Microbiol. Biotechnol. 72: 1254-1262. Lee, C. L., Kuo, T. F., Wang, J. J., Pan, T. M. 2007. Red mold rice ameliorates impairment of memory and learning ability in intracerebroventricular amyloid beta-infused rat by repressing amyloid beta accumulation. J. Neurosci. Res. 85: 3171-3182. Lee, C. L., Wang, J. J., Pan, T. M. 2008. Red mold rice extract represses amyloid beta peptide-induced neurotoxicity via potent synergism of anti-inflammatory and antioxidative effect. Appl. Microbiol. Biotechnol. 79: 829-841. Lee, C. L., Kung, T. H., Wu, C. L., Hsu, Y. W. Pan, T. M. 2010a. Monascin and ankaflavin act as novel hypolipidemic and high-density lipoprotein cholesterol-raising agents in red mold dioscorea. J. Agric. Food Chem. 58: 9013-9019. Lee, C. H., Lee, C. L., Pan, T. M. 2010b. A 90-D toxicity study of Monascus-fermented products including high citrinin level. J. Food Sci. 75: 91-97. Lefer, D. J. 2002. Statins as potent anti-inflammatory drugs. Circulation. 106: 2041-2042. Maron, D. J., Fazio, S., Linton, M. F., 2001. Current perspectives on statins. Circulation. 2001. 101: 207-213. Martinkova, L., Patakova-Juzlova, P., Krent, V., Kucerova, Z. Havlicek, V., Olsovsky, P., Hovorka, O., Rihova, B., Vesely, D., Vesela, D., Ulrichova, J., Prikrylova, V. 1999. Biological activities of oligoketide pigments of Monascus purpureus. Food Addit. Contam. 16: 15-24. Moghadasian, M. H., Mcmanus, B. M., Godin, D. V., Rodrigues, B., Frohlic, J. J. 1999. Proatherogenic and antiatherogenic effects of probucol phytosterols in apoliprotein E-deficient mice. Circulation. 99: 1733-1739. Mohammad, A. Z., Suzanne, O., David, A. C. 2002. Drugs targeting the renin–angiotensin–aldosterone system. Nat. Rev. Drug Discov. 1: 621-636. Omar, M. A., Bardage, J. P., Cox, T. S. 2001. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann. Pharmacother. 2001. 35: 1096-1107. Pearson, T. A., Terry, P. 1994. What to advise patients about drinking alcohol. JAMA. 272: 967-968. Reaven, G. M. 1988. Role of insulin resistance in human disease. Diabetes. 37: 1595-1607. Roddy, E. 2008. Hyperuricemia, gout, and lifestyle factors. J. Rheumatol. 35: 1689-1691. Ross, R. 1999. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340: 115–126. Sake, F. 1983. Induction of | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/54774 | - |
dc.description.abstract | 高血壓與心血管疾病相關的併發症是國人重要的十大死因,患者一旦發現罹患高血壓,便需長期監控血壓並積極改善生活習慣,甚至服藥控制血壓。降血壓藥物多具有副作用,不當服用降壓藥物常會造成無法挽回的傷害。紅麴已有千年的使用歷史,紅麴發酵產物含有降血壓物質 γ-胺基丁酸 (γ-aminobutyric acid, GABA),為抑制性神經傳導物質,可引起血管擴張。以 Monascus purpureus NTU 568 紅麴山藥發酵產物連續八週餵食自發性高血壓大鼠 (spontaneously hypertensive rats, SHR) 已被證實能顯著降低收縮壓 26 mmHg 與舒張壓 22 mmHg (p<0.05),作用溫和且不會對肝腎造成損害。本研究以隨機雙盲試驗將輕、中度的高血壓患者分為安慰劑組與治療組,並給予治療組 M. purpureus NTU 568 紅麴山藥產品 8 週,觀察在人體臨床試驗輔助調節血壓的效果。結果顯示治療組 11 位受試者中有 4 位受試者的收縮壓下降 ≧ 10 mmHg,收縮壓由 141.6 ± 12.0 下降至 133.9 ± 14.4 mmHg,平均下降 7.7 mmHg。治療組 11 位受試者中有 5 位受試者舒張壓下降 ≧ 10 mmHg,舒張壓由 91.7 ± 8.1 下降至 84.8 ± 7.4 mmHg,平均下降 6.9 mmHg,試驗前後達顯著差異 (p<0.05),但無組間差異。紅麴山藥不會對受試者肝、腎及肌肉組織造成損害亦無電解質失衡的現象。本研究亦發現紅麴山藥能有效降低治療組血清中三酸甘油酯及總膽固醇,並提升高密度脂蛋白膽固醇、減少低密度脂蛋白膽固醇的含量,達到心血管保健的效果。 | zh_TW |
dc.description.abstract | Hypertension and cardiovascular complications are the leading cause of death of compatriots. Once patients suffer from hypertension, they need long-term monitoring of blood pressure and actively improve the living habits. Even more, take medication to control blood pressure. Antihypertensive drugs usually have side effects, improper use of antihypertensive medications often cause irreparable harm. The application of Monascus species in food, medicine, and industry dates back over a thousand years. Monascus-fermented products containing antihypertensive substance γ-amino butyric acid (GABA), an inhibitory neurotransmitter, can cause blood vessels to dilate. Oral administration of red mold dioscorea fermented by Monascus purpureus NTU 568 to spontaneously hypertensive rats (SHR) for eight weeks has been shown to significantly reduce systolic blood pressure 26 mmHg and diastolic blood pressure 22 mmHg (p<0.05) and will not have liver and kidney damage. In this study, a double-blind placebo-controlled model was undertaken. Patients with mild to moderate hypertension were randomly assigned to placebo and treatment groups. Treatment group was given red mold dioscorea (fermented by M. purpureus NTU 568) for 8 weeks to observe the effect of regulating blood pressure in human clinical trials. The results showed that systolic blood pressure of 4 subjects decreased greater than or equal to 10 mmHg in 11 subjects of treatment group. Systolic blood pressure decreased from 141.6 ± 12.0 to 133.9 ± 14.4 mmHg, the average dropped 7.7 mmHg. Diastolic blood pressure decreased from 91.7 ± 8.1 to 84.8 ± 7.4 mmHg, the average dropped 6.9 mmHg. Diastolic blood pressure of 5 subjects decreased greater than or equal to 10 mmHg in 11 subjects of treatment group. The result showed a significant difference (p<0.05), although there was no significant difference between the placebo and treatment groups. Red mold dioscorea did not cause electrolyte imbalance and damage between liver, kidney and muscle tissue of subjects. The study also found that red mold dioscorea treatment could effectively reduce serum triglycerides and total cholesterol, increase high-density lipoprotein cholesterol, and reduce low-density lipoprotein cholesterol levels to achieve cardiovascular health. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T03:38:16Z (GMT). No. of bitstreams: 1 ntu-104-R01b22040-1.pdf: 6550282 bytes, checksum: 43761f8a2587107ffabffc631f1201c0 (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 縮寫表…………………………………………………………………………………… I
中文摘要………………………………………………………………………………… IV 英文摘要………………………………………………………………………………… V 目錄……………………………………………………………………………………… VII 圖目錄…………………………………………………………………………………… X 表目錄…………………………………………………………………………………… XI 第壹章 文獻回顧…………………………………………………………………….…. 1 ㄧ、代謝症候群…………………………………………………………………….… 1 二、高血脂症 (hyperlipidemia) 與血脂異常 (dyslipidemia)..……………......……. 3 (ㄧ) 血脂的定義與種類………………………………………………………………. 3 (二) 高血脂的定義與分類…………………………..………………………………... 5 (三) 高血脂症與心血管疾病………………………………………………….……… 7 (四) HMG-CoA 還原酶與降血脂藥物……………………………………………….. 8 三、高血壓之回顧與研究……………………..………………………………………. 10 (一) 高血壓之定義與分類……..……………………………………………………... 10 (二) 血壓之調控………………………...………………………………….…………. 11 (三) 降血壓藥物治療…….……………………………………………….…………... 13 四、紅麴菌之文獻回顧………………………………………………………………… 15 (一) 紅麴菌種之特性…………………………………………………………………. 15 (二) 紅麴之固態發酵…………….…………………………………………………… 16 (三) 紅麴在傳統食品上之應用………………………………………………………. 18 (四) 紅麴二次代謝產物於藥食同源中之功效成分…………………………………. 20 (五) M. purpureus NTU 568 紅麴菌株於預防醫學之相關研究與應用…………… 23 第貳章 研究動機與目的……………………………………………………………….. 29 第參章 材料與方法…………………………………………………………………….. 30 ㄧ、研究設計…………………………………………………………………………… 30 二、受試者挑選………………………………………………………………………… 30 (一) 選擇標準…………………………………………………………………………. 30 (二) 排除標準…………………………………………………………………………. 32 (三) 受試者同意書…………………………………………………………………… 32 三、研究方法…………………………………………………………………………… 32 (一) 治療程序…………………………………………………………………………. 32 (二) 試驗期間所做之臨床觀察………………………………………………………. 34 (三) 主要療效或評估項目……………………………………………………………. 37 四、副作用處理………………………………………………………………………… 37 五、統計分析…………………………………………………………………………… 37 第肆章 結果與討論…………………………………………………………………….. 38 一、受試者數據之排除與選擇………………………………………………………… 38 二、21 位受試者起始資料分析……………………………………………………….. 39 三、受試者試驗 8 週前後收縮壓與舒張壓之變化………………………………….. 39 (一) 受試者試驗前後收縮壓之變化……………………………................................. 39 (二) 受試者試驗前後舒張壓之變化.………………………………………………… 45 (三) 安慰劑效應及實驗可能誤差之討論……………………………………………. 49 四、紅麴山藥粉末對受試者血脂變化影響…………………………………………… 50 (一) 試驗前後總三酸甘油酯變化……………………………………………………. 50 (二) 試驗前後總膽固醇變化…………………………………………………………. 52 (三) 試驗前後高、低密度脂蛋白膽固醇變化………………………………………... 54 五、紅麴山藥粉末對受試者安全性探討……………………………………………….. 57 (一) 肝功能指標分析………………………………………………………………..... 57 (二) 腎功能指標及電解質變化分析…………...……………………………………. 61 第伍章 結論…………………………………………………………………………….. 64 第陸章 參考文獻……………………………………………………………………….. 65 附錄一 計畫執行書許可書…………………………………………………………….. 74 附錄二 受試者同意書………………………………………………………………….. 76 附錄三 產品品質檢驗紀錄表………………………………………………………….. 81 | |
dc.language.iso | zh-TW | |
dc.title | Monascus purpureus NTU 568 發酵產物對輕、中度高血壓病患調節血壓功效隨機雙盲人體試驗之研究 | zh_TW |
dc.title | Study on the effect of regulating blood pressure of Monascus purpureus NTU 568 fermented product to mild to moderate hypertension patient in randomized, double-blind clinical trials | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 周正俊,廖啟成,蔡宗佑,陳建利 | |
dc.subject.keyword | 紅麴發酵產物,紅麴山藥,高血壓,γ-胺基丁酸,人體臨床試驗, | zh_TW |
dc.subject.keyword | Monascus-fermented products,red mold dioscorea,hypertension,γ- amino butyric acid (GABA),clinical trials, | en |
dc.relation.page | 81 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-03-30 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科技學系 | zh_TW |
顯示於系所單位: | 生化科技學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 6.4 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。